bioeconomyNordic Bioproducts Group opens its first...Finnish Nordic Bioproducts Group has opened a production facility to produce advanced cellulosic materials wit the start-up’s AaltoCell technology more ➔
Swiss Biotech DaySwiss Biotech Report reporting record tu...The Swiss biotech sector proved robust growth in 2023. Revenues in 2023 increased by CHF500m to CHF7.3bn. Capital investment grew to CHF2bn – just betweeen 2021 (CHF3.4bn) and 2022 (CHF1.3bn). more ➔
Drug DiscoveryIpsen puts US$1.8bn in pipeline expansio...Ipsen SA and RNA splicing modifier specialist Skyhawk Therapeutics Inc have entered a US$1.8bn licencing option deal in rare neurological disorders. more ➔
AMDSeabelife SAS to develop next-gen dry AM...French drug maker Seabelife SAS will use a €1.5m price money to develop a new dual-acting necroptosis blocker to reduce cell death in geographic atrophy. more ➔
AmphiStar BVfinancingAmphiStar BV secures €6m to expand produ...Waste based biosurfactants producer Amphistar BV has closed a €6m funding round led by the European Circular Bioeconomy Fund (ECBF), Qbic III and Flanders Future Tech Fund (FFTF). more ➔
HIVNaobios and Sumagen partner to develop H...Vaccine maker Sumagen Co. Ltd has launched a cGMP manufacturing partnership with French Naobios SAS for clinical testing of Sumagen’s inactivated HIV vaccine candidate. more ➔
Industrial BiotechSolar Foods starts Factory01Finnish Solar Foods Oy has started microbial production of its protein powder Solein in Factory 01, Solar Foods’ first commercial-scale production facility in Vantaa, Finland. more ➔
ApprovalShock: Adrenomed AG gets FDA fast track...German AdrenoMed AG has got FDA Fast Track designation for its targeted septic shock medicine enibarcimab that restores endothel integrity. more ➔
CollaborationLonza AG enters R&D collaboration w...ALS specialist NeuroSense Therapeutics Ltd announces it will be collaborating with Swiss Lonza AG to identify exosome-based biomarkers to advance theranostics in neurodegeneration. more ➔
NeurologyLonza AG enters R&D collaboration wi...ALS specialist NeuroSense Therapeutics Ltd announces it will be collaborating with Swiss Lonza AG to identify exosome-based biomarkers to advance theranostics in neurodegeneration. more ➔
AmphiStar BV
